Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
- PMID: 21436444
- DOI: 10.1126/science.1203486
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
Abstract
Understanding how the immune system affects cancer development and progression has been one of the most challenging questions in immunology. Research over the past two decades has helped explain why the answer to this question has evaded us for so long. We now appreciate that the immune system plays a dual role in cancer: It can not only suppress tumor growth by destroying cancer cells or inhibiting their outgrowth but also promote tumor progression either by selecting for tumor cells that are more fit to survive in an immunocompetent host or by establishing conditions within the tumor microenvironment that facilitate tumor outgrowth. Here, we discuss a unifying conceptual framework called "cancer immunoediting," which integrates the immune system's dual host-protective and tumor-promoting roles.
Similar articles
-
Cancer immunoediting: from immunosurveillance to tumor escape.Nat Immunol. 2002 Nov;3(11):991-8. doi: 10.1038/ni1102-991. Nat Immunol. 2002. PMID: 12407406 Review.
-
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105. Ann N Y Acad Sci. 2013. PMID: 23651186 Free PMC article.
-
[The immune system - how does anti-tumor immunity arise ?].Oncol Res Treat. 2014;37 Suppl 4:2-5. doi: 10.1159/000366431. Epub 2014 Sep 30. Oncol Res Treat. 2014. PMID: 25301189 German. No abstract available.
-
The immune system--is it relevant to cancer development, progression and treatment?Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. doi: 10.1016/j.clon.2007.10.011. Epub 2007 Nov 26. Clin Oncol (R Coll Radiol). 2008. PMID: 18037277 Review.
-
Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?Eur J Med Res. 2001 Aug 27;6(8):323-32. Eur J Med Res. 2001. PMID: 11549514 Review.
Cited by
-
Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?Cancer Cell Int. 2024 Oct 27;24(1):355. doi: 10.1186/s12935-024-03525-9. Cancer Cell Int. 2024. PMID: 39465401 Free PMC article. Review.
-
Mechanism and Application Prospects of NLRC3 Regulating cGAS-STING Pathway in Lung Cancer Immunotherapy.Int J Med Sci. 2024 Oct 7;21(13):2613-2622. doi: 10.7150/ijms.102328. eCollection 2024. Int J Med Sci. 2024. PMID: 39439455 Free PMC article. Review.
-
Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. N Engl J Med. 2013. PMID: 23724867 Free PMC article. Clinical Trial.
-
Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation.Nat Immunol. 2024 Oct;25(10):1858-1870. doi: 10.1038/s41590-024-01932-8. Epub 2024 Aug 21. Nat Immunol. 2024. PMID: 39169233
-
Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.Eur Arch Otorhinolaryngol. 2024 Apr;281(4):1971-1989. doi: 10.1007/s00405-024-08474-7. Epub 2024 Feb 5. Eur Arch Otorhinolaryngol. 2024. PMID: 38315178
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous